Skip to content

Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices

Feasibility Study of New Subcutaneous Glucose Sensor With Recording Devices - Phase 3 Group

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04020822
Enrollment
19
Registered
2019-07-16
Start date
2019-07-29
Completion date
2019-08-27
Last updated
2020-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes, Type 2 Diabetes

Keywords

Acetaminophen

Brief summary

The purpose of Phase 3 Group is to evaluate the impact of acetaminophen on the performance of Guardian Sensor (3) during 11 days of wear (approximately 264 hours) in subjects with insulin requiring diabetes,18-75 years of age.

Detailed description

The study is a multi-center, prospective single-arm design without controls. All subjects will be assigned to treatment for 11 days of sensor wear. Each subject will wear 4 Guardian Sensor (3)s, and each will be connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter. Subjects will not use sensor glucose values for diabetes management. On days 1, 3, 5, and 6, subjects will be asked to measure blood glucose (BG) using a home glucose meter approximately every 20 minutes for 5 hours. Subjects will be asked to take one gram of acetaminophen orally on days 3, 5, and 6 of sensor wear. On day 11, devices will be removed, data uploaded from the study meter and transmitter or recorder, skin assessment will be performed, and the subject's participation in the study will be completed.

Interventions

DEVICEGuardian Sensor (3)

Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.

Sponsors

Medtronic Diabetes
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is 18-75 years of age at time of screening 2. A clinical diagnosis of type 1 or type 2 diabetes as determined by investigator, for at least the last 12 months 3. Subject is using insulin to treat their diabetes 4. Subject agrees to comply with the study protocol requirements 5. Subject is willing to perform self-monitoring of blood glucose approximately every 20 minutes during FST

Exclusion criteria

1. Subject has history of allergy to acetaminophen or has been told by health care provider they may not ingest acetaminophen 2. Subject reports history of liver cirrhosis or problems with liver that a health care provider told them they should not use acetaminophen because of liver disorder. 3. Subject is unable to tolerate tape adhesive in the area of sensor placement 4. Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g. psoriasis, rash, Staphylococcus infection) 5. Subject is actively participating in or plans to enroll in an investigational study (drug or device), other than this study, wherein they have received treatment from an investigational drug or device 6. Subject has a positive urine pregnancy test at time of screening 7. Subject is female, sexually active without the use of contraception, able to become pregnant or plans to become pregnant during the course of the study 8. Subject is unwilling to participate in study procedures.

Design outcomes

Primary

MeasureTime frameDescription
Accuracy of Sensor Glucose Before and After Acetaminophen AdministrationAssessed up to 11 days, frequent sample testing recordings from the three-hour period leading to and after Acetaminophen ingestion on days 3, 5, and 6 reportedAccuracy (mean absolute relative difference) between the primary sensor values and meter BG values during the hour leading to and two hours after ingestion of acetaminophen. Primary sensor will be assigned to sensor number one (inserted in arm). Mean Absolute Relative Difference = Mean of ((absolute difference of meter and sensor blood glucose values / meter glucose values) \* 100). Note that the results reported below for one hour leading to and two hours after acetaminophen ingestion were pooled together across multiple testing days (days 3, 5, and 6).

Countries

United States

Participant flow

Participants by arm

ArmCount
Subjects Wearing Guardian Sensor (3)s
Each subject will wear 4 Guardian Sensor (3)s connected to a Guardian Link (3) Transmitter and/or Guardian Connect Transmitter for 11 days of sensor wear. Guardian Sensor (3): Guardian Sensor (3) connected to Guardian Link (3) Transmitter and/or Guardian Connect Transmitter.
19
Total19

Baseline characteristics

CharacteristicSubjects Wearing Guardian Sensor (3)s
Age, Continuous31.9 years
STANDARD_DEVIATION 13.5
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
17 Participants
Region of Enrollment
United States
19 participants
Sex: Female, Male
Female
14 Participants
Sex: Female, Male
Male
5 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 19
other
Total, other adverse events
0 / 19
serious
Total, serious adverse events
0 / 19

Outcome results

Primary

Accuracy of Sensor Glucose Before and After Acetaminophen Administration

Accuracy (mean absolute relative difference) between the primary sensor values and meter BG values during the hour leading to and two hours after ingestion of acetaminophen. Primary sensor will be assigned to sensor number one (inserted in arm). Mean Absolute Relative Difference = Mean of ((absolute difference of meter and sensor blood glucose values / meter glucose values) \* 100). Note that the results reported below for one hour leading to and two hours after acetaminophen ingestion were pooled together across multiple testing days (days 3, 5, and 6).

Time frame: Assessed up to 11 days, frequent sample testing recordings from the three-hour period leading to and after Acetaminophen ingestion on days 3, 5, and 6 reported

Population: Only data from 13 subjects were evaluated due to data loss.

ArmMeasureGroupValue (MEAN)Dispersion
Subjects Wearing Guardian Sensor (3)sAccuracy of Sensor Glucose Before and After Acetaminophen Administration(-1, 0] hour of Acetaminophen Ingestion9.46 PercentStandard Deviation 4.63
Subjects Wearing Guardian Sensor (3)sAccuracy of Sensor Glucose Before and After Acetaminophen Administration(0, 1] hour of Acetaminophen Ingestion12.02 PercentStandard Deviation 6.53
Subjects Wearing Guardian Sensor (3)sAccuracy of Sensor Glucose Before and After Acetaminophen Administration(1, 2] hour of Acetaminophen Ingestion16.98 PercentStandard Deviation 10.96

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026